Who is sponsoring NCT07073534?

NCT07073534 is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd..

What drugs are being tested in NCT07073534?

Interventions in NCT07073534: SHR-1501, Adebrelimab.

What condition does NCT07073534 study?

NCT07073534 studies Patients With Advanced or Metastatic Malignant Tumors.

Is NCT07073534 still recruiting?

NCT07073534 is currently recruiting now. Last updated 20 January 2026.

Last reviewed 2026-01-20 · How we verify

NCT07073534

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I/II Clinical Study on the Tolerability, Safety and Efficacy of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Recruiting now Phase 1/Phase 2 Last updated 20 January 2026

What this trial tests

Phase 1/Phase 2 trial testing SHR-1501, Adebrelimab in Patients With Advanced or Metastatic Malignant Tumors in 203 participants. Currently enrolling.

Timeline

24 July 2025

Primary endpoint
1 December 2027

1 December 2027

Quick facts

Lead sponsor	Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase	Phase 1/Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	203
Start date	24 July 2025
Primary completion	1 December 2027
Estimated completion	1 December 2027
Sites	1 location across China

Drugs / interventions tested

SHR-1501, Adebrelimab — full drug profile →

Conditions studied

Patients With Advanced or Metastatic Malignant Tumors — all drugs for Patients With Advanced or Metastatic Malignant Tumors →

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Patients With Advanced or Metastatic Malignant Tumors. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Dose-limiting toxicity
Time frame: 21 Days or 28 days
evaluate the safety in the doses escalation
Maximum tolerated dose or Maximum-administered dose
Time frame: Approximately 1 years
evaluate the safety in the doses escalation
Recommended Phase 2 dose (RP2D)
Time frame: Approximately 2years.
evaluate the safety and curative effect in the doses escalation
Objective response rate(ORR)
Time frame: Approximately 2 years
Preliminary evaluation of the effectiveness of the combination of SHR-1501 and Adebrelimab
The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)
Time frame: 21 Days，Approximately 2 years
Preliminary safety of the effectiveness of the combination of SHR-1501 and Adebrelimab

Sponsor's own description

This study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion. Objective: To evaluate the objective response rate (ORR), safety and tolerability of the combination of SHR-1501 and adibelizumab in the treatment of advanced malignant tumors, and to provide the recommended dose (RP2D) for subsequent clinical studies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Hengrui Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06877247 — A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism · Phase 1 · completed
NCT06649292 — SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or M · Phase 3 · recruiting
NCT06654440 — A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy · Phase 2 · recruiting
NCT06639347 — A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma · Phase 1, PHASE2 · recruiting
NCT06605222 — A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07073534 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Hengrui Pharmaceutical Co., Ltd.
Last refreshed: 20 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07073534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing